Glenmark Life Sciences share price

ABOUT Glenmark Life Sciences

• Industry Biotechnology & Drugs
• ISIN INE03Q201024
• BSE Code 543322
• NSE Code GLS

Glenmark Life Sciences Limited is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as anti-fungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of approximately 1198 KL.

Glenmark Life Sciences Management

• Yasir Rawjee Chief Executive Officer, Managing Director, Executive Director
• Tushar Mistry Chief Financial Officer, Senior Vice President
• Mathew George Senior Vice President, Head of Regulatory Affairs
• Rudalf Corriea Company Secretary, Compliance Officer
• Palle Acharyulu Group Vice President - Research & Development
• Vinod Naik Head of Technical Operations, Whole Time Director
• Navin Agrawal Head - Corporate Quality
• Sumantra Mitra Head - Human Resources